Brief: MEI Pharma Reports Initial Data from Clinical Study Evaluating ME-344 In Combination With Bevacizumab In Relapsed Metastatic Colorectal Cancer Patients
Brief: MEI Pharma Says It Will Not Proceed With Second Capital Return Under 2023 Anson And Cable Car Cooperation Agreement
Brief: MEI Pharma Reports Update From Clinical Study Evaluating Oral CDK9 Inhibitor Voruciclib In Combination With Venetoclax
Brief: Mei Pharma Files For Mixed Shelf Of Up To $100 Million- SEC Filing
MEI Pharma Inc reports results for the quarter ended in December - Earnings Summary
MEI Pharma Inc expected to post a loss of $1.32 a share - Earnings Preview
Brief: Mei Pharma Reports Clinical Data On Oral Cdk9 Inhibitor Voruciclib At Ash2023
Advisory: Alert wrongly tagged to MEI Pharma withdrawn
Brief: Mei Pharma Declares Special Cash Dividend Of $1.75 Per Share Of Common Stock
Brief: Mei Pharma Enters Into Agreement With Anson Funds And Cable Car Capital
Brief: MEI Pharma Inc - Files Definitive Consent Revocation Statement
Brief: Mei Pharma Inc Believes That The Anson And Cable Car Group’S Actions Are Not In The Best Interests Of The Company Or Its Stockholders.
Brief: Anson & Cable Car Capital Have Delivered Letter To Mei Pharma Stockholders
Brief: Mei Pharma Adopts Limited-Duration Stockholder Rights Plan
Brief: Mei Pharma Issues Statement Regarding Anson And Cable Car's Opportunistic Actions
Brief: Anson And Cable Car Send Letter To MEI Pharma Stockholders
MEI Pharma Inc expected to post a loss of $2.41 a share - Earnings Preview
Brief: Mei Pharma Inc Confirms Receipt Of Director Nominations From Anson And Cable Car
MEI Pharma Inc expected to post a loss of $2.41 a share - Earnings Preview